Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Red blood cell (RBC) transfusion is a standard clinical intervention used in the management of sickle cell disease (SCD) to increase oxygen-carrying capacity and reduce the concentration of sickle hemoglobin (HbS). This specific entry refers to the 'Age of Blood in Sickle Cell Transfusion' study (NCT03704922), a randomized Phase 2/3 trial led by the University of North Carolina at Chapel Hill. The trial investigates the impact of RBC storage duration, comparing 'older' units (stored for 30 days or more) to 'fresher' units (stored for 10 days or less) in adult SCD patients receiving chronic outpatient transfusions. The study aims to determine if older RBC units contribute to increased inflammation, monocyte/macrophage activation, and higher infection rates due to biochemical changes during storage, such as phosphatidylserine expression and the release of non-transferrin bound iron (NTBI).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on red blood cell transfusion (University of North Carolina at Chapel Hill).